Overview

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Inte

Status:
Completed

Trial end date:
2017-12-24

Target enrollment:

Participant gender:

Summary

Trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of treatment intensification.

Phase:

Phase 3

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Hypoglycemic Agents
Insulin
Insulin Aspart
Insulin degludec, insulin aspart drug combination
Insulin Glargine
Insulin, Globin Zinc
Insulin, Long-Acting